Standard BioTools Inc.
As of Oct 22, 2026, Standard BioTools is in Stage 4, the downtrend phase, now in week 17 (since Jun 29, 2026). It closed at $0.64, 61.9% below its 52-week high and below its 200-day average, which is falling.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop ther… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LAB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LAB among Medical Devices87th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …87 | LAB | Stage 4 · wk 17 | 23 | −13.5% |
Standard BioTools: quick answers
What stage is Standard BioTools in?
As of Oct 22, 2026, Standard BioTools (LAB) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 29, 2026 and is in week 17. What the four stages mean
Is Standard BioTools in an uptrend?
No. Standard BioTools is in a Stage 4 downtrend. It trades 32.1% below its 200-day average, which is falling.
How far is Standard BioTools from its 52-week high?
Standard BioTools closed at $0.64 on Oct 22, 2026, 61.9% below its 52-week high of $1.68. Its 52-week low is $0.63.
How has Standard BioTools performed over the past year?
As of Oct 22, 2026, Standard BioTools is down 51.5% over the past year and down 49.6% so far in 2026.
Which sector and industry is Standard BioTools in?
Standard BioTools is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.